Akebia Therapeutics to Report Q2 2025 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics will release its Q2 2025 financial results on August 7, 2025, and host a conference call at 8:00 a.m. EDT to discuss the results and recent business highlights. Investors are encouraged to register in advance for the webcast. The company is focused on advancing treatments for kidney disease and improving patient outcomes.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of people impacted by kidney disease, has announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss the results and recent business highlights. Investors are encouraged to register in advance for the webcast, which will be available via the Investors section of Akebia’s website [1].

The financial results will provide insights into the company's performance during the second quarter of 2025, including revenue, expenses, and other key financial metrics. Additionally, the conference call will offer an opportunity for investors to hear about recent business developments and strategic initiatives.

Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, Massachusetts. The company's mission is to develop innovative therapies for kidney disease, with a focus on improving patient outcomes. It has received FDA approval for its drug Vafseo (vadadustat) for treating anemia in adults with chronic kidney disease who have been on dialysis for at least three months [2].

In recent months, Akebia Therapeutics has been active in granting stock options to new employees as part of their employment inducement packages. These options are subject to continued employment with the company and follow a 4-year vesting schedule [3]. The company's stock options program is in compliance with Nasdaq Listing Rule 5635(c)(4).

Investors and financial professionals are advised to closely follow the financial results and conference call to gain a comprehensive understanding of Akebia Therapeutics' performance and future prospects.

References:

[1] https://www.barchart.com/story/news/33776594/akebia-therapeutics-to-report-second-quarter-2025-financial-results-and-discuss-recent-business-highlights
[2] https://www.morningstar.com/news/globe-newswire/9504787/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4
[3] https://www.stocktitan.net/news/AKBA/